Long-term mycophenolate monotherapy in human leukocyte antigen (HLA)-identical living-donor kidney transplantation.
Although recipients of a first HLA-identical living-donor kidney transplant seem to need less immunosuppression, there are no guideline recommendations for these patients, and few prospective trials are available.


METHODS
We analyzed all PRA-negative patients who received a first kidney transplant from an HLA-identical living donor. The patients received no antibody induction. An intraoperative bolus of 500 mg of methylprednisolone was administered. Then, steroid therapy was withdrawn within one week. Tacrolimus and mycophenolate treatment were started 3 days before transplantation with tacrolimus target levels of 4 to 8 ng/mL. In the absence of rejection, tacrolimus was withdrawn between 3 and 12 months post-transplant to reach mycophenolate mofetil monotherapy of 2 g/day or equivalent.


RESULTS
Six patients were treated with the above protocol. At last follow-up, graft and patient survival were 100%. MDRD glomerular filtration rates were 54, 60, and 62 mL/min at 3 months, 12 months and last follow-up, respectively. None of the patients developed PRA post-transplant. One episode of acute rejection Banff IA occurred 9 years after transplantation due to non-adherence with good outcome after treatment. The mean number of concomitant drugs given with mycophenolate was 2.6. Four patients needed antihypertensive drugs.


CONCLUSIONS
Steroid-free de novo treatment and calcineurin-inhibitor weaning with mycophenolate monotherapy is feasible in first HLA-identical kidney transplantation from a living sibling.
Blanca
B
Gascó
Ignacio
I
Revuelta
Ana
A
Sánchez-Escuredo
Miquel
M
Blasco
Federico
F
Cofán
Nuria
N
Esforzado
Luis F
LF
Quintana
María José
MJ
Ricart
José Vicente
JV
Torregrosa
Josep M
JM
Campistol
Federico
F
Oppenheimer
Servicio de Nefrología y Trasplante Renal, Hospital Clínic, Villarroel 170 08036 Barcelona, Spain. fdiekman@clinic.ub.es.
Fritz
F
Diekmann